Veraxa Biotech Holding AG (VRXA) Total Non-Current Liabilities (2024 - 2025)

Veraxa Biotech Holding AG (VRXA) has reported Total Non-Current Liabilities for 2 consecutive years, with $112.6 million the latest figure, recorded in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities rose 92.74% year-over-year to $112.6 million; the trailing twelve-month figure through Dec 2025 stood at $112.6 million (up 92.74% YoY), and the FY2025 full-year result was $112.6 million, up 92.74% from the prior year.
• Total Non-Current Liabilities advanced to $112.6 million in Q4 2025 per VRXA's latest filing, from $58.4 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $112.6 million in Q4 2025 to a low of $58.4 million in Q4 2024.